The nominal deal value is $2.6B. The 174% premium is one of the largest ever for a biotech deal of this size.
Nestle already owned ~20% of AIMT based on investments dating back to 2016 and including, most recently, a $200M addition following FDA approval of Palforzia (#msg-153675586).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.